Aptus Pharma has outlined its next phase of growth focused on developing its own manufacturing capabilities, strengthening its pan-India presence and exploring opportunities in international markets.

The Board of Directors has approved a proposal to raise INR 44.88 crore through a preferential issue of equity shares to identified investors. The proposal is subject to approval of the members at the forthcoming Annual General Meeting (AGM) scheduled for September 14, 2026, and other applicable statutory and regulatory approvals.

Subject to receipt of the requisite approvals and completion of the preferential issue, the company proposes to utilise INR 25 crore toward capital expenditure comprising land acquisition, manufacturing plant structure, hi-tech storage facilities and vehicles; INR 10 crore toward working-capital requirements; and INR 9.88 crore toward general corporate purposes, including operational requirements, corporate exigencies, strategic growth, business expansion, strengthening of the financial position, enhancement of net worth and reduction of debt. The issue proceeds are proposed to be utilised within 36 months from the date of receipt of funds, in accordance with the disclosures contained in the AGM Notice.

As part of its long-term strategy, the company proposes to develop its own manufacturing capabilities and aspires to meet approximately 20 percent of its product requirements through inhouse manufacturing. The initiative is expected to strengthen control over product quality, supply-chain management and product availability and support the development of its own brand portfolio. Its implementation will be subject to commercial and technical feasibility, availability of funds and applicable regulatory approvals.

On the domestic front, the company intends to progressively strengthen its sales and distribution presence across West, Central, East and South India as it moves toward broader Pan-India operations.

The company also intends to explore opportunities in select international markets, including Africa, the Middle East and Latin America, through product registrations, export partnerships and other permissible business arrangements. Such expansion will be pursued progressively, subject to commercial viability, market conditions and applicable regulatory approvals.

Tejash Hathi, Managing Director, Aptus Pharma, said, “Our next phase is focused on developing Aptus Pharma into a stronger and more integrated pharmaceutical enterprise. Our strategic direction is clear—from marketing-led operations toward manufacturing capabilities, from a regional presence toward pan-India operations, and from domestic markets toward suitable international opportunities. Subject to the requisite approvals, the proposed INR 44.88 crore preferential issue is expected to strengthen our capital base and support capital expenditure, working-capital requirements and long-term business growth. Our aspiration to progressively meet approximately 20 percent of our product requirements through in-house manufacturing forms an important part of this strategy.”